Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Tryptamine Therapeutics ( (AU:TYP) ).
Tryptamine Therapeutics Limited has commenced patient recruitment for a groundbreaking clinical trial to treat Binge Eating Disorder (BED) using their proprietary TRP-8803, in collaboration with Swinburne University. The trial aims to assess the safety, efficacy, and feasibility of TRP-8803 when administered with psychotherapy. This initiative could significantly impact the treatment landscape for BED, the most common eating disorder in the US, by offering a potentially effective solution for a condition often associated with severe psychiatric comorbidities.
More about Tryptamine Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Their lead program, TRP-8803, is an IV-infused psilocin formulation aimed at addressing the limitations of oral psilocybin, such as reducing the time to onset and controlling the duration of the psychedelic experience.
Average Trading Volume: 1,775,916
Technical Sentiment Signal: Sell
Current Market Cap: A$47.48M
For detailed information about TYP stock, go to TipRanks’ Stock Analysis page.